Methylene blue reduces incidence of early postoperative cognitive disorders in elderly patients undergoing major non-cardiac surgery: An open-label randomized controlled clinical trial (2020)

Peer-Reviewed Study · Deng Y; Wang R; Li S; Zhu X; Wang T; Wu J; Zhang J · October 19, 2020

Deng Y et al., 2020-10-19: Open-label randomized trial in 248 elderly patients having major non-cardiac surgery; 2 mg/kg intravenous methylene blue within 60 minutes of induction versus saline. Postoperative delirium fell from 24.2% to 7.3% and early postoperative cognitive dysfunction at day 7 from 40.2% to 16.1%.

The incidence of early POCD at postoperative 7th day in MB group was also less than that in control group (16.1% vs. 40.2%, OR = 0.30, 95% CI: 0.16-0.57, p < 0.001).

Deng Y et al., 2020-10-19: Open-label randomized trial in 248 elderly patients having major non-cardiac surgery; 2 mg/kg intravenous methylene blue within 60 minutes of induction versus saline. Postoperative delirium fell from 24.2% to 7.3% and early postoperative cognitive dysfunction at day 7 from 40.2% to 16.1%. Study type: prospective randomized OPEN-LABEL controlled trial (no blinding, no placebo injection). N=248 (124/124). Dose 2 mg/kg IV over 60 min, single perioperative infusion – far above the 0.5-4 mg/kg 'low dose' nootropic range in unit terms but a single exposure. Country: China (Fudan University). Funder not recorded in the abstract. Declared conflicts not recorded in the abstract. Outcome is prevention of perioperative cognitive disorder in surgical patients, not enhancement of clarity or focus in healthy people; a published comment on the trial exists (J Clin Anesth 2021;71:110206). Also filed as MTC-028, MTK-40 (claims C3, C4, C8). Study type: randomized trial.